FR2088019B1 - - Google Patents

Info

Publication number
FR2088019B1
FR2088019B1 FR7016802A FR7016802A FR2088019B1 FR 2088019 B1 FR2088019 B1 FR 2088019B1 FR 7016802 A FR7016802 A FR 7016802A FR 7016802 A FR7016802 A FR 7016802A FR 2088019 B1 FR2088019 B1 FR 2088019B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7016802A
Other languages
French (fr)
Other versions
FR2088019A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RABOT ETS DAVID
Original Assignee
RABOT ETS DAVID
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RABOT ETS DAVID filed Critical RABOT ETS DAVID
Priority to FR7016802A priority Critical patent/FR2088019A1/fr
Priority to GB1249771A priority patent/GB1352415A/en
Priority to ES71390924A priority patent/ES390924A1/es
Priority to BE766808A priority patent/BE766808A/xx
Publication of FR2088019A1 publication Critical patent/FR2088019A1/fr
Application granted granted Critical
Publication of FR2088019B1 publication Critical patent/FR2088019B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
FR7016802A 1970-05-03 1970-05-08 Esters of 2 and 6-substituted nicotinic acids - with vasomotor active Granted FR2088019A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR7016802A FR2088019A1 (en) 1970-05-08 1970-05-08 Esters of 2 and 6-substituted nicotinic acids - with vasomotor active
GB1249771A GB1352415A (en) 1970-05-03 1971-04-30 Esters of substituted nicotine acids
ES71390924A ES390924A1 (es) 1970-05-03 1971-05-06 Procedimiento para la preparacion de derivados del acido nicotinico.
BE766808A BE766808A (fr) 1970-05-03 1971-05-06 Nouveaux esters d'acide nicotinique substitue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7016802A FR2088019A1 (en) 1970-05-08 1970-05-08 Esters of 2 and 6-substituted nicotinic acids - with vasomotor active

Publications (2)

Publication Number Publication Date
FR2088019A1 FR2088019A1 (en) 1972-01-07
FR2088019B1 true FR2088019B1 (zh) 1974-08-30

Family

ID=9055254

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7016802A Granted FR2088019A1 (en) 1970-05-03 1970-05-08 Esters of 2 and 6-substituted nicotinic acids - with vasomotor active

Country Status (1)

Country Link
FR (1) FR2088019A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671060B2 (en) 2006-10-26 2010-03-02 Astrazeneca Ab Heteroaryl benzamide derivatives
US7745475B2 (en) 2004-06-05 2010-06-29 Astrazeneca Ab Heteroaryl benzamide derivatives as GLK activators
US7842694B2 (en) 2005-07-09 2010-11-30 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7943607B2 (en) 2005-05-27 2011-05-17 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US8071585B2 (en) 2009-04-09 2011-12-06 Astrazeneca Ab Therapeutic agents
US8076481B2 (en) 2009-02-13 2011-12-13 Astrazeneca Ab Chemical process 632
US8093252B2 (en) 2009-02-13 2012-01-10 Astrazeneca Ab Crystalline polymorphic form of glucokinase activator
US8143263B2 (en) 2008-08-04 2012-03-27 Astrazeneca Ab Therapeutic agents

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210877B2 (zh) * 1972-11-08 1977-03-26
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CA2581619A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
WO2008075073A1 (en) 2006-12-21 2008-06-26 Astrazeneca Ab Novel crystalline compound useful as glk activator
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1037380A (en) * 1964-01-20 1966-07-27 Orgamol Sa Process for the production of basic esters of pyridine-carboxylic acids
JPS644086A (en) * 1987-06-26 1989-01-09 Yokogawa Electric Corp Quantum resistance standard

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745475B2 (en) 2004-06-05 2010-06-29 Astrazeneca Ab Heteroaryl benzamide derivatives as GLK activators
US7943607B2 (en) 2005-05-27 2011-05-17 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7842694B2 (en) 2005-07-09 2010-11-30 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7671060B2 (en) 2006-10-26 2010-03-02 Astrazeneca Ab Heteroaryl benzamide derivatives
US7964725B2 (en) 2006-10-26 2011-06-21 Astrazeneca Ab Heteroarylbenzamide derivatives for use in the treatment of diabetes
US8143263B2 (en) 2008-08-04 2012-03-27 Astrazeneca Ab Therapeutic agents
US8076481B2 (en) 2009-02-13 2011-12-13 Astrazeneca Ab Chemical process 632
US8093252B2 (en) 2009-02-13 2012-01-10 Astrazeneca Ab Crystalline polymorphic form of glucokinase activator
US8071585B2 (en) 2009-04-09 2011-12-06 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
FR2088019A1 (en) 1972-01-07

Similar Documents

Publication Publication Date Title
FR2088019B1 (zh)
AU1473870A (zh)
AU2044470A (zh)
AU2085370A (zh)
AU1517670A (zh)
AU1716970A (zh)
AU1833270A (zh)
AU2017870A (zh)
AU1872870A (zh)
AU1974970A (zh)
AU1918570A (zh)
AU1581370A (zh)
AU1591370A (zh)
AU1603270A (zh)
AU1689770A (zh)
AU1789870A (zh)
AU1832970A (zh)
AU2144270A (zh)
AU2131570A (zh)
AU2130770A (zh)
AU2130570A (zh)
AU2119370A (zh)
AU2115870A (zh)
AU1841070A (zh)
AU2112570A (zh)

Legal Events

Date Code Title Description
ST Notification of lapse